Development of a novel UHPLC-MS/MS method for quantitative analysis of pirtobrutinib in rat plasma: application to pharmacokinetic study
Abstract Bruton’s tyrosine kinase (BTK) inhibitors play a critical role in the treatment of mantle cell lymphoma (MCL). pirtobrutinib, a new, highly selective, non-covalent BTK inhibitor, was approved by the FDA for the treatment of MCL, chronic lymphocytic leukemia (CLL), and small lymphocytic lymp...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2025-02-01
|
| Serier: | BMC Chemistry |
| Fag: | |
| Online adgang: | https://doi.org/10.1186/s13065-025-01424-2 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|